Pharma Phorum
DECEMBER 22, 2022
The life sciences industry is flexing towards innovation in new areas, faster than ever before, and increasing patient care in astonishing ways. Decentralised oncology trials, for example, have shown actual predictive outcome value.
Bio Pharma Dive
DECEMBER 19, 2022
The OK caps a long development journey for the treatment, which was previously turned back by the agency. Ferring doesn’t expect it to be available until the second half of next year, however
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 21, 2022
Artificial intelligence (AI) continued to stay in the news with several high-profile deals this year, as the pharmaceutical industry readily took to adopting AI models to improve drug discovery.
The FDA Law Blog
DECEMBER 22, 2022
By Jeffrey N. Gibbs & Sara W. Koblitz — Back in June, when Congress was negotiating the User Fee Acts, FDA asked Congress to add in some provisions reversing several lawsuits that it had just lost.
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
The Pharma Data
DECEMBER 20, 2022
Boehringer Ingelheim announces appointments to Board of Managing Directors. Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors.
Bio Pharma Dive
DECEMBER 21, 2022
Lynparza’s authorization in first-line prostate cancer comes days after U.S. regulators delayed a decision on the same indication, a potential sign of the FDA’s concerns around PARP blockers
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Phorum
DECEMBER 19, 2022
A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population.
The Pharma Data
DECEMBER 20, 2022
Astellas, Seagen and Merck Announce FDA Acceptance of sBLA for PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer. Astellas Pharma Inc.
Bio Pharma Dive
DECEMBER 20, 2022
The proposed bill would strengthen rules around confirmatory testing, help speed product withdrawals and set up a panel of agency officials to better coordinate policy
Pharmaceutical Technology
DECEMBER 21, 2022
Moderna and the UK government have entered a ten-year strategic collaboration to build a messenger ribonucleic acid (mRNA) research, development and manufacturing facility in the country. The latest development comes after the parties announced an agreement in principle in June this year.
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Fierce Pharma
DECEMBER 22, 2022
Pfizer, Sanofi settle first California Zantac case slated for trial: report. zbecker. Thu, 12/22/2022 - 12:38
The Pharma Data
DECEMBER 20, 2022
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer.
Bio Pharma Dive
DECEMBER 22, 2022
The pharma will pay the Chinese drugmaker $175 million for access to seven preclinical antibody-drug conjugates, deepening ties established this year
Pharmaceutical Technology
DECEMBER 18, 2022
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting variation to the marketing authorization (MA) for Moderna ’s Spikevax bivalent Original/Omicron BA.1 mRNA-1273.214) booster for usage in children aged six to 11 years.
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Pharma Times
DECEMBER 21, 2022
ACD856 has also been shown across preclinical studies to improve cognition and memory
The Pharma Data
DECEMBER 18, 2022
Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology.
Bio Pharma Dive
DECEMBER 21, 2022
The pharma dosed the first patient in a Phase 2 study testing a treatment it hopes could compete with closely-watched weight-loss drugs from Lilly, Novo Nordisk and Amgen
Pharmaceutical Technology
DECEMBER 22, 2022
Fentanyl is a powerful opioid (a narcotic analgesic that is at least partly synthetic) that is being trafficked in increasing quantities from Mexico to the US by cartels.
BioPharma Reporter
DECEMBER 19, 2022
Replay, the genome writing company reprogramming biology by writing and delivering big DNA, has launched its third product company, Kaleibe, a HSV gene therapy company targeting genetic brain disorders. Bio Developments
Pharma Times
DECEMBER 20, 2022
ColoAlert research could identify advanced adenomas among colorectal cancer patients
Bio Pharma Dive
DECEMBER 19, 2022
Removal of the partial study suspension, which the agency imposed last December after a case of persistent anemia, helps clear the way for Bluebird to submit an approval application early next year
Pharmaceutical Technology
DECEMBER 19, 2022
Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate.
Fierce Pharma
DECEMBER 19, 2022
Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo. fkansteiner. Mon, 12/19/2022 - 14:06
Pharma Times
DECEMBER 22, 2022
Study uses carious drug combinations to increase survival among lung cancer patients
Bio Pharma Dive
DECEMBER 19, 2022
The company said its experimental drug helped patients with the fatty liver disease while also improving fibrosis. One analyst called the readout a “major win” for Madrigal and the NASH field
Pharmaceutical Technology
DECEMBER 19, 2022
Last week, the US Federal Reserve raised interest rates for the seventh time this year in a continuing bid to stave off worries of a recession. The International Monetary Fund predicts that real gross domestic product (GDP) growth in the US will fall from 1.6%
Pharma Phorum
DECEMBER 22, 2022
Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna.
Pharma Times
DECEMBER 22, 2022
Vital financing will help boost diagnosis, treatment and prospects of patient groups
Bio Pharma Dive
DECEMBER 19, 2022
Glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus, will be the responsibility of Roche, which will pay out royalties
Pharmaceutical Technology
DECEMBER 20, 2022
Biotechnology firm LianBio has announced that Pfizer opted in to secure the right to develop and commercialise the respiratory syncytial virus (RSV) therapeutic candidate, sisunatovir, in Mainland China, Hong Kong, Macau, and Singapore.
BioPharma Reporter
DECEMBER 20, 2022
The US Food and Drug Administration (FDA) has approved the first gene therapy for patients with high-risk form of bladder cancer. Markets & Regulations
Pharma Times
DECEMBER 21, 2022
Therapy treats patients with metastatic non-small cell lung cancer and has completed successful phase 3 trial
Bio Pharma Dive
DECEMBER 20, 2022
While long anticipated trial data were technically positive, analysts questioned whether drugs aimed at ‘TIGIT’ will prove a meaningful treatment addition
Pharmaceutical Technology
DECEMBER 23, 2022
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection.
Expert insights. Personalized for you.
79 
Let's personalize your content